The Covid pandemic set back progress in another pandemic, HIV, to devastating effect. Few likely know that as well as Rashad Burgess, the head of Gilead Sciences’ HIV community operations and…
Just a few weeks after Otezla notched a Phase III win and hit all primary and secondary endpoints for a trial in genital psoriasis, Amgen’s blockbuster drug Otezla gets yet another OK from the FDA.…
New research from Johns Hopkins shows convalescent plasma may work in the outpatient space, which could be key as the Omicron variant has extinguished several monoclonal antibody treatments. The…
PhaseBio is blaming the impact of COVID-19 on manufacturing for the decision to end development of a mid-stage cardiovascular disease treatment.
Beginning in January, Americans will be able to visit a website where they can have the tests mailed directly to their homes at no charge.
Bob Duggan — the billionaire investor famous for turning Pharmacyclics from a penny stock to a $20 billion company — placed a handsome bet on the company’s new antibiotic for C. difficile infection…
Whether you call it the new normal, the next normal or just a major shift, pharma marketing will never be the same thanks to the Covid-19 pandemic. From the acceleration of digital strategies and…
Sanofi is betting $1 billion on a preclinical pipeline of anti-cancer T-cell engagers. The upfront outlay, plus up to $225 million in milestones, is set to give Sanofi ownership of West Coast immuno…
After showing for the first time the potential of an anti-tau therapy in Alzheimer’s disease, Roche-partnered AC Immune is capitalizing on the massive moment underway in research for the…
Ambys Medicines wants to go after diseases impacting the liver, a key regenerative organ, with cell therapies. The Takeda-partnered biotech snagged $47 million from the Japanese Pharma and venture…
